Assessment of pharmacodynamic interactions of two-drug combinations of five selected cytostatics in an in vitro model of human melanoma: an isobolographic analysis
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026-02 · 399 (4) · 5843-5854
DOI: 10.1007/s00210-025-04712-9 ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, online erschienen am 12.11.2025. Verfasst von Paula Wróblewska-Łuczka und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Occupational Medicine, Medical University of Lublin, Lublin, Poland. paula.wroblewska-luczka@umlub.edu.pl. Hauptthemen laut MEDLINE: Melanoma, Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Uniwersytet Medyczny w Lublinie.
Abstract (Originalsprache)
Melanoma ranks 17th among the most frequently diagnosed cancers, with an upward trend in incidence. Treatment of this cancer is based on surgical removal of the lesion, but when metastases or recurrence occur, immunotherapy or chemotherapy is used. Most of the drugs used are characterized by numerous side effects or drug resistance that appears after some time of use. Therefore, multi-drug therapy is more often considered. The aim of the study was to assess the nature of the pharmacodynamic interaction of five different cytostatics (in a fixed dose ratio of 1:1) using a mathematical-statistical method—isobolographic analysis. The experiments were conducted on four human malignant melanoma cell lines (A375, SK-MEL28, FM55M2, FM55P) and studied all possible (ten) pairs of combinations of five standard cancer chemotherapy drugs (based on the MTT test): cisplatin, mitoxantrone, docetaxel, vemurafenib, and selumetinib. Our experiments showed that the most advantageous combination was the combination of vemurafenib with docetaxel for human melanoma lines—statistically significant synergy interaction for three cell lines. Also noteworthy are the combinations: cisplatin with mitoxantrone, vemurafenib with selumetinib, and vemurafenib with mitoxantrone. From a therapeutic point of view, the worst combination is cisplatin with docetaxel and cisplatin with selumetinib (interaction with a tendency to antagonism for the two cell lines). Monotherapy for melanoma does not produce good results, so the best drug combinations are sought, which would improve long-term, durable patient response and overcome drug resistance. It would also be good if the combination used caused fewer side effects than monotherapy, and this could be achieved in the case of using synergistic combinations.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Occupational Medicine, Medical University of Lublin, Lublin, Poland. paula.wroblewska-luczka@umlub.edu.pl.
- Department of Occupational Medicine, Medical University of Lublin, Lublin, Poland.
Förderung
- Uniwersytet Medyczny w Lublinie
Zitieren
APA
Wróblewska-Łuczka, P., Góralczyk, A., & Łuszczki, J. J. (2026). Assessment of pharmacodynamic interactions of two-drug combinations of five selected cytostatics in an in vitro model of human melanoma: an isobolographic analysis. Naunyn-Schmiedeberg's Archives of Pharmacology, 399(4), 5843-5854. https://doi.org/10.1007/s00210-025-04712-9
Vancouver
Wróblewska-Łuczka P, Góralczyk A, Łuszczki JJ. Assessment of pharmacodynamic interactions of two-drug combinations of five selected cytostatics in an in vitro model of human melanoma: an isobolographic analysis. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026;399(4):5843-5854. doi:10.1007/s00210-025-04712-9
BibTeX
@article{Wrblewskauczka2026,
author = {Wróblewska-Łuczka, Paula and Góralczyk, Agnieszka and Łuszczki, Jarogniew J},
title = {Assessment of pharmacodynamic interactions of two-drug combinations of five selected cytostatics in an in vitro model of human melanoma: an isobolographic analysis},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
volume = {399},
number = {4},
pages = {5843--5854},
doi = {10.1007/s00210-025-04712-9}
}
EUVIMED